Innate Pharma (IPHYF) Total Non-Current Liabilities (2017 - 2025)

Innate Pharma's Total Non-Current Liabilities history spans 9 years, with the latest figure at $55.6 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 24.84% year-over-year to $55.6 million; the TTM value through Dec 2025 reached $55.6 million, down 24.84%, while the annual FY2025 figure was $55.6 million, 25.8% down from the prior year.
  • Total Non-Current Liabilities reached $55.6 million in Q4 2025 per IPHYF's latest filing, down from $74.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $105.9 million in Q4 2022 to a low of $55.6 million in Q4 2025.
  • Average Total Non-Current Liabilities over 5 years is $83.4 million, with a median of $90.0 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: fell 27.4% in 2021, then increased 15.48% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $91.7 million in 2021, then rose by 15.48% to $105.9 million in 2022, then fell by 15.02% to $90.0 million in 2023, then decreased by 17.79% to $74.0 million in 2024, then decreased by 24.84% to $55.6 million in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Total Non-Current Liabilities are $55.6 million (Q4 2025), $74.0 million (Q4 2024), and $90.0 million (Q4 2023).